CD38 and Miyoshi myopathy: ISA was selected initially based on its in vitro ability to directly induce MM cell death independently of effector cells and independently of Fc fragment binding to FcRs by binding the CD38 activating the classical caspase, lysosome death pathways, lysosomal membrane permeabilization, and cathepsin hydrolase release (62).